Su Li, Zhang Mingwei, Zhang Weijian, Cai Chuanshu, Hong Jinsheng
Department of Radiation Oncology, First Affiliated Hospital of Fujian Medical University Key Laboratory of Radiation Biology (Fujian Medical University), Fujian Province University Fujian Key Laboratory of Individualized Active Immunotherapy, Fujian Medical University, Fuzhou, Fujian, China.
Medicine (Baltimore). 2017 Mar;96(11):e6364. doi: 10.1097/MD.0000000000006364.
Pretreatment hematologic parameters of the inflammatory response, including lymphocyte, neutrophil, and platelet counts, neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio, have emerged as prognostic factors for patients with cancer. This systematic review and meta-analysis aimed to summarize the association between the hematologic markers and prognosis of nasopharyngeal carcinoma (NPC).
A systematic search of PubMed, Google Scholar, MEDLINE, EMBASE, Web of Science, and the Cochrane Library was conducted up to April 2016. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were extracted and synthesized to examine prognostic outcomes including cancer-specific survival (CSS), overall survival (OS), progression-free survival (PFS), distant metastasis-free survival, and local relapse-free survival (LRFS).
Fourteen studies comprising 11,651 NPC patients were ultimately included, and all eligible studies were conducted in East Asia. The OS, CSS, PFS, distant metastasis-free survival, and LRFS risks differed among patients according to hematologic marker levels. All of the parameters were associated with prognostic outcomes in patients with NPC. NLR and lymphocyte counts were most commonly reported. A high NLR was significantly associated with poor NPC prognosis (pooled HR 1.42, 95% CI 1.21-1.67 for CSS; pooled HR 1.77, 95% CI 1.41-2.23 for OS; pooled HR 1.67, 95% CI 1.36-2.06 for PFS; pooled HR 1.64, 95% CI 1.15-2.34 for LRFS). High lymphocyte count indicated favorable NPC prognosis (pooled HR 0.72, 95% CI 0.64-0.81 for OS; pooled HR 0.71, 95% CI 0.56-0.91 for PFS).
Meta-analysis indicated that NLR and lymphocyte counts could be prognostic predictors in NPC for East Asian population. Patients with a high NLR or low lymphocyte count had poor prognosis. However, due to the limitation of included population, the conclusion was limited to East Asian patients only.
炎症反应的预处理血液学参数,包括淋巴细胞、中性粒细胞和血小板计数、中性粒细胞与淋巴细胞比值(NLR)、淋巴细胞与单核细胞比值以及血小板与淋巴细胞比值,已成为癌症患者的预后因素。本系统评价和荟萃分析旨在总结血液学标志物与鼻咽癌(NPC)预后之间的关联。
截至2016年4月,对PubMed、谷歌学术、MEDLINE、EMBASE、科学网和考克兰图书馆进行了系统检索。提取并综合了具有95%置信区间(95%CI)的风险比(HR),以检验包括癌症特异性生存(CSS)、总生存(OS)、无进展生存(PFS)、无远处转移生存和无局部复发生存(LRFS)在内的预后结果。
最终纳入了14项研究,共11651例NPC患者,所有符合条件的研究均在东亚地区进行。根据血液学标志物水平,患者的OS、CSS、PFS、无远处转移生存和LRFS风险有所不同。所有参数均与NPC患者的预后结果相关。最常报告的是NLR和淋巴细胞计数。高NLR与NPC预后不良显著相关(CSS的合并HR为1.42,95%CI为1.21-1.67;OS的合并HR为1.77,95%CI为1.41-2.23;PFS的合并HR为1.67,95%CI为1.36-2.06;LRFS的合并HR为1.64,95%CI为1.15-2.34)。高淋巴细胞计数表明NPC预后良好(OS的合并HR为0.72,95%CI为0.64-0.81;PFS的合并HR为0.71,95%CI为0.56-0.91)。
荟萃分析表明,NLR和淋巴细胞计数可能是东亚人群NPC的预后预测指标。NLR高或淋巴细胞计数低的患者预后较差。然而,由于纳入人群的局限性,该结论仅适用于东亚患者。